Metformin—Comparison with Other Therapies in Ovulation Induction in Polycystic Ovary Syndrome
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is a common hormonal condition in women and is associated with insulin resistance, disorders of weight and metabolism, hyperandrogenism, anovulation, infertility, and menstrual irregularities. Its etiology is uncertain, but current theories emphasize genetic and intrauterine origins coupled with environmental factors such as diet and altered lifestyle patterns. Effective treatment of PCOS remains controversial but needs to be divided into the main requirements of the patient, depending on whether they are seeking cosmetic improvement, restoration of menstrual function, fertility, weight loss, or amelioration of metabolic changes. In recent years, so-called insulin-sensitizing agents such as metformin have found wide usage in PCOS based on the relationship between hyperinsulinism and ovarian hyperandrogenism. The introduction of these agents has led to questioning of established therapeutic pathways for ovulation induction, which have been based on clomiphene citrate and gonadotropins such as FSH. Much has been written about the value of laparoscopic ovarian drilling whereby diathermy or application of laser surgery to the ovary leads to enhanced ovulation, reduction in testosterone, and increased live birth rates. Although the procedure is less damaging to the ovary than wedge resection, concern has been expressed that adhesions may form that convert anovulatory infertility into tubal obstruction. Nevertheless, there is widespread use of this procedure by gynecologists who either plan a laparoscopy to perform ovarian drilling or operate on polycystic ovaries that are discovered incidentally at laparoscopic surgery. In this issue, Palomba et al. (1) address the optimal intervention in cases of PCOS in which fertility is the major problem. Patients who had PCOS and were resistant to clomiphene citrate were enrolled and randomized into one of two groups. Both groups underwent laparoscopy with one having a diagnostic procedure only, followed by metformin 850 mg twice per day for 6 months. The second group also underwent laparoscopy but had additional ovarian drilling. The latter group was then given placebo for the next 6 months. At the end of the study, the total ovulation rate was not significantly different between the two groups but the pregnancy rate was higher in the metformin group, whereas the miscarriage rate was lower. As a consequence, the live birth rates were significantly different between the two groups in favor of metformin treatment. Economic analysis of the two therapies strongly favored the metformin group. This well-conducted study indicates that metformin is extremely effective in inducing ovulation and pregnancy and is also justified in terms of cost benefits compared with ovarian surgery. Women with anovulatory PCOS respond well to weight loss and lifestyle modification as shown by a number of studies in which approximately 5% weight loss will restore ovulation and reduce miscarriage rates (2, 3). Intervention therapies have varied but generally include a hypocaloric diet, exercise, and the use of group therapy. There is no doubting the efficacy of lifestyle intervention, but there has been great difficulty in instituting appropriate weight loss programs. There have been few randomized controlled trials looking at the effect of weight loss in PCOS, although Pasquali et al. (4) have shown that the addition of metformin is more effective than that of placebo alone when dietary intervention is attempted in women with PCOS. More weight loss, greater reduction in waist circumference, more decrease in visceral fat mass, and lower levels of testosterone were found in women who took metformin rather than placebo. Unfortunately, many women with PCOS find lifestyle intervention difficult to institute and maintain or are in the normal weight range and may not benefit from weight loss. In these women with PCOS, medical or surgical therapies have been widely used to induce ovulation and pregnancy. Clomiphene citrate is a first-line drug that has been available for many years and significantly increases ovulation by interfering with feedback mechanisms in the hypothalamic pituitary ovarian axis (5). It is a safe oral therapy and has relatively few side effects other than an increase in multiple pregnancy rates. It should be used with effective monitoring by blood tests and ultrasound. Rates of ovulation are reported at approximately 70% after the first cycle, although pregnancy rates are much lower. Women who fail to ovulate on low doses of clomiphene are exposed to higher doses of the drug, and those who still do not ovulate are described as clomiphene resistant. Clomiphene resistance is more common in women who are heavier, have higher androgen concentrations, and have excess LH. The recent introduction of aromatase inhibitors instead of clomiphene citrate opens a new avenue in oral therapy for ovulation induction, but more information is required before aromatase inh
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clark, A. M., Thornley, B., Tomlinson, L., Galletley, C., & Norman, R. J. (1998) · Human Reproduction · doi:10.1093/humrep/13.6.1502 · Cited by 789
Self-citationMetformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786
Self-citationPasquali, R., Gambineri, A., Biscotti, D., Vicennati, V., Gagliardi, L., Colitta, D., Fiorini, S., Cognigni, G. E., Filicori, M., & Morselli-Labate, A. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6738 · Cited by 635
Palomba, S., Orio, F., Nardo, L. G., Falbo, A., Russo, T., Corea, D., Doldo, P., Lombardi, G., Tolino, A., Colao, A., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0689 · Cited by 177
Cited by
Palomba, S., Orio, F., Falbo, A., Manguso, F., Russo, T., Cascella, T., Tolino, A., Carmina, E., Colao, A., & Zullo, F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0110 · Cited by 279
Exercise therapy in polycystic ovary syndrome: a systematic review
Harrison, C. L., Lombard, C. B., Moran, L. J., & Teede, H. J. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmq045 · Cited by 267
Nutrition and reproduction in women
The ESHRE Capri Workshop Group (2006) · Human Reproduction Update · doi:10.1093/humupd/dmk003 · Cited by 255
Hamed, H. O., Hasan, A. F., Ahmed, O. G., & Ahmed, M. A. (2010) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2009.08.033 · Cited by 41
RetractedMokaberinejad, R., Rampisheh, Z., Aliasl, J., & Akhtari, E. (2019) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2018.1541232 · Cited by 28
“The recommended therapeutic intervention to control the clinical symptoms include oral contraceptives for the treatment of menstrual irregularities and hirsutism, along with androgen suppression drugs, such as spironolactone and finasteride, as well as metformin due to its effect on insulin secretion and blood glucose…”
BackgroundInfluential
Metadata
- Authors
- Norman, R. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-10
- Volume
- 89
- Issue
- 10
- Pages
- 4797-4800
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2068815843
- Cited by
- 38
- References
- 4
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.